<?xml version="1.0" encoding="UTF-8"?>
			<!DOCTYPE bbbc.edwiserinternational.com [
<!ELEMENT channel (title,link,description,language,managingEditor,webMaster,copyright,image,item,item)>
<!ELEMENT title (#PCDATA)>
<!ELEMENT link (#PCDATA)>
<!ELEMENT language (#PCDATA)>
<!ELEMENT managingEditor (#PCDATA)>
<!ELEMENT webMaster (#PCDATA)>
<!ELEMENT copyright (#PCDATA)>

<!ELEMENT image (title,link,url,width,height)>
<!ELEMENT url (#PCDATA)>
<!ELEMENT width (#PCDATA)>
<!ELEMENT height (#PCDATA)>

<!ELEMENT item (title,pubDate,link,author,comments,category,description)>
<!ELEMENT pubDate (#PCDATA)>
<!ELEMENT author (#PCDATA)>
<!ELEMENT comments (#PCDATA)>
<!ELEMENT category (#PCDATA)>
<!ELEMENT description (#PCDATA)>

]>
		<channel>
<title>Bioscience-Biotechnology-Pharmacology-Communications-ISSUE VOLUME Volume 1 ISSUE Issue 1</title>
<link>http://bbbc.edwiserinternational.com/rss-feed.php</link>
<description>
Bioscience-Biotechnology-Pharmacology-Communications: VOLUME Volume 1 ISSUE Issue 1, Jan-June 2026
</description>
<language>en-us</language>
<managingEditor>editor@edwiserinternational.com</managingEditor>
<webMaster>editor@edwiserinternational.com</webMaster>
<copyright>editor@edwiserinternational.com</copyright>
<image>
<title>Bioscience-Biotechnology-Pharmacology-Communications-ISSUE VOLUME Volume 1 ISSUE Issue 1</title>
<link>http://bbbc.edwiserinternational.com/rss-feed.php</link>
<url>http://bbbc.edwiserinternational.com/img/logo1.png</url>
<width>360</width>
<height>109</height>
</image><item>
		<title>Safety-and-Antihyperglycemic-Activity-of-Pancra-Free-An-Antidiabetic-Remedy-Formulated-by-an-Ivorian-Traditional-Practitioner</title>
		<pubDate>27-Mar-2026</pubDate>
<link>http://bbbc.edwiserinternational.com/admin/uploads/rgbXhv.pdf</link>
		<author>Effo-KE-Kouakou-MAAJ-Dah-O-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science,Clinical Science</category>
		<description>{<![CDATA[Diabetes remains a public health problem due to the limitations of conventional treatments. Traditional medicine offers an alternative. Pancras Free is a remedy produced by an Ivorian traditional practitioner to treat diabetes. This study aimed to evaluate the safety and antihyperglycemic activity of Pancras Free.The safety of Pancras Free was evaluated according to OECD 423 and OECD 407 guidelines. The hypoglycemic risk of Pancras Free at doses of 4.5, 9, and 18 mg/kg was investigated. The anti-hyperglycemic activity of the same doses was evaluated in an induced-hyperglycemia animal model. Blood glucose levels of rats were checked before hyperglycemia was induced and then every hour for 4 hours.Pancras Free did not cause any signs of clinical toxicity or lethality up to 2000 mg/kg. When administered once daily for 28 days, Pancras Free also showed no signs of clinical, hematological, or biochemical toxicity. Pancras Free did not cause a significant decrease in fasting blood glucose levels. Pancras Free caused a non-significant reduction in induced hyperglycemia. This decrease was more pronounced from the third hour for doses of 4.5 mg/kg and 18 mg/kg, and from the second hour at the dose of 9 mg/kg. Pancras Free demonstrates good clinical, hematological, renal, and hepatic tolerance as well as low antihyperglycemic activity without hypoglycemic risk.  Its combined use, according to the traditional practitioner's protocol, could justify its use in the treatment of diabetes.]]>}</description>
		</item><item>
		<title>Evaluation-of-Pharmacological-Management-and-Pharmacist-Led-Interventions-in-Patients-with-Congestive-Heart-Failure-A-Prospective-Observational-Study</title>
		<pubDate>27-Mar-2026</pubDate>
<link>http://bbbc.edwiserinternational.com/admin/uploads/ZRCXNL.pdf</link>
		<author>Md-Javed-Karim-Basit-Fazal</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science,Clinical Science</category>
		<description>{<![CDATA[Congestive Heart Failure (CHF) is a complex and progressive cardiovascular syndrome characterized by the heart's inability to pump blood efficiently, leading to insufficient perfusion of tissues and organs. This project critically examines the clinical, therapeutic, and pharmaceutical dimensions of CHF, emphasizing its growing impact on global and Indian healthcare systems. The pathophysiology involves neurohormonal activation, structural remodelling, and hemodynamic alterations, which contribute to hallmark symptoms such as dyspnoea, fatigue, and fluid retention.This study was conducted as a prospective observational analysis at a tertiary care hospital, evaluating 120 patients diagnosed with CHF. It incorporates data on demographic profiles, comorbidities, ejection fraction, drug utilization patterns, and adverse reactions. Pharmacological management included the use of ACE inhibitors, beta-blockers, diuretics, ARBs, MRAs, and emerging agents like ARNI and SGLT2 inhibitors. The findings revealed that pharmacist-led interventions significantly improved medication adherence (as measured by MMAS-8), reduced hospital readmission rates, and enhanced patients quality of life.The integration of pharmaceutical care into CHF management demonstrated a clear reduction in symptom burden and healthcare utilization. This report reinforces the necessity of a multidisciplinary approachcombining clinical precision with sustained patient education and counsellingto optimize outcomes. The results advocate for stronger policy support and wider implementation of pharmacist- driven models in chronic disease management, particularly in resource-limited settings.]]>}</description>
		</item></channel>